ARC-706 / Archeus Technologies - LARVOL DELTA

Archeus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic Cancer (Businesswire) - "In this first-in-human imaging and therapy study, participants will receive intravenous ARC-166 for dosimetry and patient selection, followed by ARC-706 to evaluate its safety, biodistribution, pharmacokinetics, and potential to augment anti-tumor immune response. The study also aims to determine an optimal Phase 1b dose of ARC-706 and explore changes in relevant cancer-related biomarkers."

First-in-human • Trial status • Oncology